Russia's Biocad progresses original drug against melanoma

The Russian biotech company Biocad has begun a Phase III of clinical trial of its new, original drug for the treatment of melanoma, bringing it a step closer to launching a second product for this disease.

According to the company and Russian media reports, the current stage of research is studying the use of the drug prior to surgery.

At present the situation with melanoma in Russia remains complex. At the end of 2019, almost 12,000 primary diagnoses of skin melanoma were recorded in Russia. As in the rest of the world, this figure is constantly increasing. In this regard, the launch of the new drug could be very important for dealing with the disease.